On July 23, the U.S. Food and Drug Administration (FDA) approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm in patients with chronic obstructive pulmonary disease. Read more.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.